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anti-Pneumocystis carinii activity†
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DOI: 10.1039/c0md00082ePrimacenes, novel ferrocene–primaquine conjugates, were synthesized and screened for their
antimalarial and anti-pneumocystis activity. Primacenes obtained by coupling primaquine amino acid
derivatives to ferrocenoic acid were significantly active against Pneumocystis carinii and devoid of
cytotoxicity, thus being more selective than the parent drug.Scheme 1 Synthetic routes to Primacenes 2–6: (i) 1 eq. ferrocene-
carboxylic acid, 1.1 eq. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride (EDC$HCl), 1.1 eq. triethylamine (Et3N), dry CH2Cl2,Primaquine (PQ, 1 in Scheme 1) is an antimalarial drug with
potent gametocytocidal and modest blood-schizontocidal
activity, against which no clinically relevant resistance has been
associated to date, as the few PQ-tolerant strains of Plasmodium
vivax that were so far identified were considered as most likely to
present a priori differences regarding their sensitivity to PQ than
true development of resistance to the drug.1 PQ is also useful for
the treatment of Pneumocystis infections1–4 caused by Pneumo-
cystis jirovecii (formerly P. carinii f. sp. hominis2,3), which is
a common cause of pneumonia in immunocompromised indi-
viduals and frequently the first serious illness encountered by
HIV-infected patients.4–8 P. jirovecii also infects other immuno-
compromised individuals such as those undergoing cancer
therapy and organ and bone marrow transplants.9 The mecha-
nisms by which PQ exerts its activity against either of these two
pathogens are yet unveiled,1,4,10 but interference with electron
transport in the respiratory chain, oxidative stress and impair-
ment of mithocondrial function have been considered.1,10
Ferrocene (Fc) has been used in the preparation of bioactive
organometallic structures, such as Fc-conjugates of peptides and
nucleotides.11 Fc-conjugates of clinically relevant drugs have also
been described as, for instance, arene isosteres in dopamine
receptor ligands12 or organometallic antimalarials derived from
4-aminoquinolines.13 Indeed, the most emblematic example of
the contribution of the Fc moiety to the improvement of a drug is
that of Ferroquine (FQ), a chloroquine (CQ) isostere with an Fc-90 min in ultra-sound bath (USB) at r.t.; (ii) 1.1 eq. Na-tert-butoxy-
carbonyl-protected amino acid N-hydroxy-succinimide ester
(BocAA1OSu), 1.1 eq. Et3N, dry CH2Cl2, 24 h at r.t.; (iii) neat
CF3COOH, 30 min at r.t., then drop-wise aq. Na2CO3 to pH 11 followed
by extraction with CHCl3; (iv) 1.1 eq. BocGlyOSu, dry CH2Cl2, 24 h at
r.t.; (v) dry propanone (2 eq. per day), 3 days in refluxing CH3OH with
4 A molecular sieves; (vi) 5 eq. SnCl2, dropwise conc. HCl, 24 h at r.t.,
then drop-wise aq. 8 M NaOH to pH 11 followed by extraction with
CHCl3; (vii) 1.5 eq. 6-bromo-hexylferrocene, 3.5 h in refluxing Et3N.
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This journal is ª The Royal Society of Chemistry 2010based side chain that is 22 times more potent than CQ itself and
now under clinical trials.14,15 FQ was found to, like CQ, inhibit
hemozoin formation14,15 but, remarkably, it is equally active
against CQ-sensitive and CQ-resistant strains of both
P. falciparum14,15 and P. vivax.16 This prompted Biot and co-
workers to further investigate other mechanisms of action for
FQ complementary to a CQ-like interference with hematinMed. Chem. Commun., 2010, 1, 199–201 | 199
Fig. 1 Linear correlation found between IC50 values of Primacenes 3a–e
and clogP values estimated (see Table 1) for model amides 8a–e.
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View Onlinepolymerization.15,17 These studies allowed important differences
to be established between CQ and FQ in terms of basicity and
lipophilicity, with FQ being 100 times more lipophilic than CQ at
cytosolic pH and to be expectedly 50-fold more concentrated
than CQ at the putative acidic pH of the parasite’s food vacuole
(FV).15 This led to the assumption that FQ properties could be
due to a highly efficient: (i) partition into, and/or hydrophobic
collapse with, parasitic membrane lipids; (ii) concentration at the
lipid site of hemozoin formation; (iii) maintenance of toxic
hematin in the aqueous environment, by creating a barrier at the
water-lipid interface.15 Additionally, the same research group
found that under conditions mimicking the environment of the
parasite’s FV, FQ undergoes a Fenton-like redox reaction that
generates highly reactive hydroxyl radicals known both to be
rather pernicious towards membrane unsaturated fatty acids,
and to promote chain reactions through peroxidation products.17
Such redox behaviour, which cannot be reproduced by CQ under
similar conditions, possibly underlies the distinctive properties of
FQ, not only concerning its blood-schizontocidal potency but
also, and especially, its apparent lack of propensity to rapidly
induce parasite resistance.15–17
The above findings have sprang a number of research studies
where Fc was used to enhance the antimalarial activity of fluo-
roquinolones like ciprofloxacin,18 or to create novel dual-action
hybrid drugs with highly promising results.19–22 In this connec-
tion, we hypothesized that insertion of the ferrocene core into
either PQ or its derivatives might enhance their anti-plasmodial
and anti-pneumocystis activities, mainly due to the redox prop-
erties of the Fc moiety.
Our previous research has been focused on Imidazoquines,
a new class of imidazolidin-4-one peptidomimetic derivatives of
PQ that display antimalarial and anti-pneumocystis activity
while being resistant to premature metabolic inactivation by
oxidative deamination.23–31 Thus, we have prepared a first
generation of ferrocene–PQ conjugates (2–5) that we have called
the Primacenes, by coupling ferrocenecarboxylic acid to amino
groups present in PQ-based scaffolds (Scheme 1). We have alsoTable 1 Cytotoxicity, anti-Pneumocystis activity and anti-Plasmodium activ
Compound
Activity against blood-stage
P.falciparum W2a Activity against P. ca
IC50 in mM IC50 in mM/mg mL
1d
1 3.3b 1.77 (0.46)
2 >10 (>100)
3a >10 28.2 (14.9)
3b >10 23.1 (13.2)
3c >10 8.33 (4.52)
3d 8.33 2.69 (1.57)
3e >10 1.15 (0.71)
4 >10 46.8 (27.4)
5 >10 35.5 (20.2)
6 >10 5.76 (2.55)
7 9.1c 23 (8.3)c
a CQ-resistant strain, against which highly active drugs have IC50s at the low n
23 c Taken from ref. 19 d Drug anti-Pneumocystis activity scale: highly active
to 0.099 mg ml1), marked (IC50s from 0.10 to 0.99 mg ml
1), moderate (IC50s fr
(i.e., inactive; IC50s of $50 mg ml
1);32 e Calculated using the OSIRIS Pro
determined.
200 | Med. Chem. Commun., 2010, 1, 199–201synthesized structure 6, a flexible ferrocene derivative of
8-amino-6-methoxyquinoline (MAQ), the heteroaromatic core
of PQ (Scheme 1). To the best of our knowledge, there is no
precedent in the literature concerning the preparation and study
of any kind of ferrocene–primaquine conjugates. Detailed
procedures on compound synthesis, chromatographic and spec-
troscopic data as well as in vitro biological evaluation against
P. falciparum and P. carinii are given in the ESI.†
Table 1 summarizes in vitro data concerning the antimalarial
and anti-pneumocystis activity of the first set of nine primacenes
prepared. The table also includes data on the cytotoxicity of the
four most active compounds against P. carinii, on A549 human
lung fibroblast carcinoma and L2 rat lung epithelial cell lines. All
assays were run in duplicate.
An immediately eye-catching observation is that, while ferro-
cenoylation of PQ and of its derivatives, including of Imidazo-
quine 7 (precursor of Primacene 5), is generally detrimental for
blood-schizontocidal activity against the CQ-resistant P. falci-
parum strain W2, the same does not apply to the compounds’
anti-Pneumocystis activity. Thus, all tested compounds, except
for the parent drug PQ (1) and for the PQ–Leucine–Ferrocene
conjugate (3d), had IC50 over 10 mM against P. falciparum.
Artemisinin, a potent blood-schizontocidal, was also included in
the screening as a comparator, and displayed an IC50 of 6.06 nM.ity of compounds 1–7
rinii (72 h)
Cytotoxicity IC50 in mM/mg
mL1
clogP for model
structures 8a–eeA549 cells L2 cells
84.6 (22.0) 83.9 (21.8) —
ND —
ND 0.93
>175 (>100) 0.52
ND 0.28
>171 (>100) 0.74
>162 (>100) 0.75
ND —
ND —
>226 (>100) —
ND —
anomolar range [e.g., IC50 for artemisinin ¼ 6.06 nM]. b Taken from ref.
(compounds with an IC50 of <0.010 mg ml
1), very marked (IC50s of 0.011
om 1.0 to 9.99 mg ml1), slight (IC50s from 10.0 to 49.9 mg ml
1), and none
perty Explorer (http://www.organic-chemistry.org/prog/peo/); ND, not
This journal is ª The Royal Society of Chemistry 2010
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View OnlineIn turn, ferrocenoylation was almost never deleterious for anti-
Pneumocystis activity, whose levels depended on the specific
compound: while direct ferrocenoylation of PQ, as in 2, deleted
the marked activity of the parent drug, the presence of an amino
acid residue between the PQ moiety and the ferrocene core (3a–e)
preserved activity, which was higher for more lipophilic struc-
tures (i.e., derived from amino acids leucine, 3d, and phenylala-
nine, 3e). Considering clogP values for the series of model amides
8a–e, which reflect the same amino acid variation as on prima-
cenes 3a–e, we find a very good linear correlation between IC50
(3a–e) values and clogP (8a–e) values (Fig. 1).
Overall, we found that, on a molar basis, primacene 3e was the
best anti-Pneumocystis agent of the set, being even more active
than PQ. In addition, neither 3e nor the other three most active
primacenes (3c, 3d and 6) were cytotoxic against any of the two
cell lines used (IC50>100 mg mL
1), in clear contrast with the
parent drug (IC50 ca. 22 mg mL
1 in both cases).
Finally, it should be mentioned that the distinct performance
of primacenes as blood-schizontocidals vs. anti-pneumocystis
agents was quite surprising, since our previous findings with PQ
derivatives drove us to the assumption that there was a certain
degree of correlation between these two types of bioactivity.27,31
At the present stage, we believe that the deletion of blood-
schizontocidal activity caused by ferrocen(o)ylation of PQ
derivatives or of MAQ is due to the fact that the final primacene
structures lack a basic amine. The relevance of such a group has
been proposed earlier33 and confirmed by our previous studies
with PQ peptide and peptidomimetic (imidazoquine) deriva-
tives.23–31 To check this hypothesis, we are now working on the
synthesis and in vitro evaluation of second-generation prima-
cenes bearing basic amino groups.
Concluding remarks
Novel primaquine-ferrocene conjugates, the Primacenes, have
been prepared and screened for their anti-Plasmodium (blood-
stage parasites) and anti-Pneumocystis activities. Primacenes
were seen to be devoid of significant antimalarial action, but one
subset was found to be moderately to markedly active against
Pneumocystis carinii. This subset included one compound, 3e,
that was more active and markedly less cytotoxic than the parent
drug, which is an unparalleled finding for PQ-based anti-Pneu-
mocystis agents. Also, to the best of our knowledge, there is no
precedent in the literature concerning the study of primaquine-
ferrocene conjugates.
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